ATE361753T1 - Die verwendung einer spezifischen dosis von fondaparinux natrium zur behandlung des akuten koronaren syndroms - Google Patents

Die verwendung einer spezifischen dosis von fondaparinux natrium zur behandlung des akuten koronaren syndroms

Info

Publication number
ATE361753T1
ATE361753T1 AT02787601T AT02787601T ATE361753T1 AT E361753 T1 ATE361753 T1 AT E361753T1 AT 02787601 T AT02787601 T AT 02787601T AT 02787601 T AT02787601 T AT 02787601T AT E361753 T1 ATE361753 T1 AT E361753T1
Authority
AT
Austria
Prior art keywords
treatment
acute coronary
coronary syndrome
specific dose
fondaparinux sodium
Prior art date
Application number
AT02787601T
Other languages
German (de)
English (en)
Inventor
Anthonie Wilhelmus A Lensing
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE361753(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE361753T1 publication Critical patent/ATE361753T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT02787601T 2001-11-13 2002-11-07 Die verwendung einer spezifischen dosis von fondaparinux natrium zur behandlung des akuten koronaren syndroms ATE361753T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13

Publications (1)

Publication Number Publication Date
ATE361753T1 true ATE361753T1 (de) 2007-06-15

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787601T ATE361753T1 (de) 2001-11-13 2002-11-07 Die verwendung einer spezifischen dosis von fondaparinux natrium zur behandlung des akuten koronaren syndroms

Country Status (36)

Country Link
US (1) US20040248848A1 (enExample)
EP (1) EP1446131B1 (enExample)
JP (1) JP4523276B2 (enExample)
KR (1) KR20050044318A (enExample)
CN (1) CN1602197A (enExample)
AP (1) AP1820A (enExample)
AR (1) AR037291A1 (enExample)
AT (1) ATE361753T1 (enExample)
AU (1) AU2002351915B2 (enExample)
BR (1) BR0212915A (enExample)
CA (1) CA2465776A1 (enExample)
CO (1) CO5580790A2 (enExample)
CY (1) CY1106765T1 (enExample)
DE (1) DE60220084T2 (enExample)
DK (1) DK1446131T3 (enExample)
EA (1) EA007325B1 (enExample)
EC (1) ECSP045041A (enExample)
ES (1) ES2287343T3 (enExample)
GE (1) GEP20074097B (enExample)
HR (1) HRP20040303B1 (enExample)
HU (1) HU228959B1 (enExample)
IL (2) IL161114A0 (enExample)
IS (1) IS2484B (enExample)
MA (1) MA27071A1 (enExample)
ME (2) MEP1108A (enExample)
MX (1) MXPA04003045A (enExample)
NO (1) NO20041320L (enExample)
NZ (1) NZ552129A (enExample)
PE (1) PE20030740A1 (enExample)
PL (1) PL206008B1 (enExample)
PT (1) PT1446131E (enExample)
RS (1) RS50906B (enExample)
SI (1) SI1446131T1 (enExample)
UA (1) UA80399C2 (enExample)
WO (1) WO2003041722A1 (enExample)
ZA (1) ZA200402464B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
JP6869894B2 (ja) * 2015-03-20 2021-05-12 オーフス ウニベルシテット リポタンパク質代謝障害の治療のためのpcsk9阻害剤
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
EP1551852A4 (en) * 2002-04-25 2007-03-21 Momenta Pharmaceuticals Inc METHOD AND PRODUCTS FOR MUCOSAL DELIVERY

Also Published As

Publication number Publication date
SI1446131T1 (sl) 2007-10-31
ECSP045041A (es) 2004-04-28
HU228959B1 (en) 2013-07-29
DK1446131T3 (da) 2007-09-10
RS50906B (sr) 2010-08-31
KR20050044318A (ko) 2005-05-12
IS7199A (is) 2004-03-29
GEP20074097B (en) 2007-05-10
CA2465776A1 (en) 2003-05-22
JP4523276B2 (ja) 2010-08-11
JP2005509007A (ja) 2005-04-07
IL161114A0 (en) 2004-08-31
PE20030740A1 (es) 2003-08-28
DE60220084T2 (de) 2008-01-10
NZ552129A (en) 2008-04-30
MA27071A1 (fr) 2004-12-20
AP2004003014A0 (en) 2004-06-30
DE60220084D1 (de) 2007-06-21
AU2002351915B2 (en) 2007-11-29
PL206008B1 (pl) 2010-06-30
IL161114A (en) 2010-11-30
WO2003041722A1 (en) 2003-05-22
UA80399C2 (en) 2007-09-25
NO20041320L (no) 2004-06-14
HRP20040303A2 (en) 2004-10-31
US20040248848A1 (en) 2004-12-09
PL369027A1 (en) 2005-04-18
AP1820A (en) 2008-01-11
CO5580790A2 (es) 2005-11-30
CY1106765T1 (el) 2012-05-23
ME00229B (me) 2011-10-10
EP1446131A1 (en) 2004-08-18
HUP0401462A3 (en) 2006-04-28
EA200400382A1 (ru) 2004-10-28
HUP0401462A2 (en) 2006-02-28
AR037291A1 (es) 2004-11-03
HRP20040303B1 (hr) 2012-02-29
ES2287343T3 (es) 2007-12-16
IS2484B (is) 2008-12-15
ZA200402464B (en) 2005-06-29
EP1446131B1 (en) 2007-05-09
BR0212915A (pt) 2004-10-13
PT1446131E (pt) 2007-08-07
EA007325B1 (ru) 2006-08-25
RS26704A (sr) 2007-02-05
HK1070561A1 (en) 2005-06-24
MEP1108A (en) 2011-02-10
CN1602197A (zh) 2005-03-30
MXPA04003045A (es) 2005-06-20

Similar Documents

Publication Publication Date Title
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60114808D1 (de) Oberflächenbehandlung von medizinischer vorrichtung
SI1425001T1 (sl) Fenetanolaminski derivati za zdravljenje respiratornih bolezni
ATE276244T1 (de) Replikationsinhibitoren des respiratorischen synzytialvirus
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE538096T1 (de) Pyridinon-derivate zur behandlung von arteriosklerose
DE60019195D1 (de) Behandlung durch Ablation von Knochenmetastasen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60239648D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Asthma
EP1274444A4 (en) COMPOUNDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS OR DISORDERS CAUSED BY THE ABUSE OF PSYCHOACTIVE SUBSTANCES
DE10194333T1 (de) Methode des Quantenrechnens
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
DE60216275D1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
EP1117431A4 (en) TREATMENT OF ACIDOSIS
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60318327D1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE314850T1 (de) Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1446131

Country of ref document: EP